Trial Profile
Phase II clinical trial evaluating the efficacy of the dual inhibition of PIK/Akt/mTor signaling pathway by PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) or de novo relapsed or refractory AML
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
- Focus Therapeutic Use
- Acronyms LAM-PIK
- 14 May 2017 Status changed from recruiting to completed.
- 15 Jul 2015 New trial record